BTK INHIBITORS FOR THE TREATMENT OF CNS MALIGNANCIESDescribed herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of CNS malignancies.Juthamas SUKBUNTHERNGPurvi JEJURKARDanielle TONEV
BTK Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaT he immune system surveils our body looking for things that don't belong, often bacteria and viruses. While cancer cells are abnormal cells that undergo unregulated cell growth, they are good at evading detection by the immune system...
参考文献: Deng T, Zhang S, Xiao M, Gu J, Huang L, Zhou X. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B-cell lymphoma. Cancer Med. 2024;1...
Research progress of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of inflammatory and immune-mediated diseases REN Weijie, CEN Lifang, ZOU Yi * School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China Abstract Bruton’s tyrosine kinase (BTK), a cytopl...
Btk inhibitors are being developed for treatment of autoimmune diseases as well as hematological cancers dependent on BCR signaling. Ibrutinib was the first FDA approved Btk inhibitor and is currently clinically used for treating mantle cell lymphoma and chronic lymphocytic leukemia. Other Btk inhibitors...
Targeting treatment resistance in chronic lymphocytic leukemia with a compound that goes beyond current BTK inhibitors https://medicalxpress.com/news/2024-02-treatment-resistance-chronic-lymphocytic-leukemia.html
[1]Whang, Jennifer A.; Chang, Betty Y. (2014). Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today. doi:10.1016/j.drudis.2014.03.021 [2]Gayko, U., et al., Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignan...
[which] usually happens in the initial cycle; however, this headache is very [brief] and goes away after the first couple of cycles. We treat it with caffeine and they do very well. If you support these patients through the headache, using the appropriate treatment, it usually does...
EP: 7.Non-Covalent BTK Inhibitors in the Treatment of CLL: Nemtabrutinib EP: 8.Fixed-Duration Venetoclax in the Treatment of CLL EP: 9.Role of Venetoclax in Patients with High-Risk CLL EP: 10.Sequencing Therapies in CLL EP: 11.Emerging Therapies in CLL ...
Factors to consider when stopping BTK inhibitor therapy include long- and short-term factors relevant to the host, the disease, and the treatment. Durability of remission after stopping BTK inhibitors likely varies by genetic markers of the disease (eg, TP53 aberration, IGHV mutation, and mutations...